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Abstract
Objective To evaluate the antitumor effects of minplatin-
lipidol suspension and emulsion.
Materials and methods Fifty rabbits with VX2 liver
tumors were randomly assigned to ten groups. Then, we
prepared four types of mixtures: a suspension of lipiodol
and miriplatin (ML), an emulsion of minplatin dissolved
with lipiodol and contrast medium (MLC) or saline (MLS),
and saline alone (S). Ratios between hpiodol and contrast
mediumノsaline volumes were 1:1/4, 1:1/2, 1:1, and 1:2
respectively. We used the same dose of minplatin (2 mg/
kg) and lipiodol (0.1 ml戊g) in each emulsion and sus-
pension group. After intra-artenal infusion, the tumor
growth rate was calculated, and sequential change of the
plasma platinum concentration, the platinum concentration
in the tumor and in surrounding normal liver tissue was
also measured.
Results Among the ten groups, the tumor growth rate was
lower in MLC and MLS groups, and the difference
between tumor treated with MLS emulsion (ratio 1: 1/2)
and ML suspension was significant (p - 0.02). The plati-
num concentration in the normal liver tissue was lower in
MLS and MLC groups血an in the ML group, and that in
the tumor was higher in the MLS and MLC emulsion (ratio
1:1/2) groups.
Conclusion We suggest that miriplatin-hpiodol emulsion
may be more effective than suspension.
Y. Tomozawa (図)・N. Nitta・S. Ohta・H. Otani
S. Watanabe・A. Sonoda・K. Tsuchiya・A. Nitta-Seko
M. Takahashi・K. Murata
Department of Radiology, Sh享ga University of Medical Science,
Seta Tsukinowa-cho, Otsu City, Shiga 520-2192, Japan
e-mail: tomozawa@belle.shiga-med.ac.jp
」) Springer
Keywords Transcatheter arterial infusion・Minplatin
Suspension・Emulsion
Introduction
The incidence of hepatoc llular carcinoma (HCC), one of
the most common malignancies worldwide, is increasing
[1]. Advances in its diagnosis and treatment have improved
the prognosis of patients with HCC [2-5]; in those with
in p rable HCC, transartenal chemoembohzation (TACE)
is the most mportant therapy. The efficacy and tumor
s lectivity of antitumor agents can be increased by injecting
an mbolic material r an oily lymphographic agent (LPD,
Lipiodol Ultra-fluid; Guerbet, Aulnay-sous-Bois, France)
via the hepatic artery. In Japan, several antitumor agents,
e.g. cisplatin [6], doxorubicin 【7】, epirubicin [8], mitomycin
C 【9], and zinostatin stimalamer [10], either suspended or
emulsi丘ed in LPD have been studied clinically, and TACE,
using emulsions of epirubicin with LPD or suspensions of
cisplatin powder (DDPH, IA-call; Nippon Kayaku, Tokyo,
Japan) in LPD followed by embolization with gelatin
sponges, is now widely used to treat patients with HCC [1 1].
Miriplatin (Miripl ; Daimppon Sumitomo Pharma,
Osaka, Japan), a novel hpophihc platinum complex with a
h gh affinity for LPD, has been developed to treat HCC
[12]. Because of its chemical properties, minplatin is
expected to yield a more stable chemoembohc compound
than the previously-used emulsions of wateトsoluble anti-
tumor agents and LPD. In animals and humans, the intra-
hepa ic arterial administration of miriplatin suspended in
LPD manifested antitumor effects against hepatic tumors
【13-17], and Okusaka et al. 【16] and Fujiyama et al. [18]
suggested the use of 20 mg/ml miriplatin suspended in
LPD to treat patients with HCC.
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Research has demonstrated that the administration of an
epirubicin suspension is a superior form of TACE com-
pared to血at of administration of an epirubicin emulsion,
with the suspension form being found superior to the
emulsion form in maintaining sustained agent release [19].
Although miriplatin has a different chemical property
compared with the water-soluble antitumor agents, no
study to date has compared the antitumor efficacy of mi-
riplatin-LPD suspensions and emulsions.
In this article, using a rabbit transplanted VX2 liver
cancer model we evaluated the antitumor effect of sus-
pensions (without solution) and emulsions (with solution)
of miriplatin-LPD and estimated the relevant mixture ratios
of miriplatin, contrast medium or saline, and LPD.
Materials and methods
VX2 liver tumor model and experimental groups
Our study was approved by the ethics committee of our
institution and abided by the regulations covering the care
and use of experimental animals. We induced the liver
tumors using the method of Haaga et al. [20]. Briefly, one
Japanese white rabbit hosting a transplanted VX2 liver
tumor was purchased from Japan SLC, Inc. (Tokyo, Japan).
When the tumor diameter reached 30 mm, the tumor was
harvested. Under sterile conditions, 2 x 2 x 2-mm pieces
of tumor tissue were dissected, placed in 10 % dimethyl
sulfoxide with 80 % Hanks'balanced salt solution, and
10 % bovine serum in pure calf serum, and stored in liquid
nitrogen until use at which time they were thawed rapidly
at 36 -C. We anesthetized 50 adult Japanese white rabbits
weighing 2.5-3.5 kg (Japan SLC, Inc.) with an mtramus-
cular (i.m.) injection of medetomidine hydrochlonde
(0.1 mg/kg, Meiji Seika Co. Ltd., Tokyo, Japan) and ket-
amine hydrochloride (25 mg化g, Sankyo Yell Yakuhin Co.
Ltd., Tokyo, Japan). For tumor implantation, a small
midline incision was made at the subxiphoid process, the
left medial lobe of the liver was exposed and exteriorized,
and a 2 × 2 × 2-mm piece ofVX2 tumor was implanted.
The abdominal muscles and skin were then closed with an
absorbable suture. The transplanted rabbits were injected
with 1.0 ml of 2.5 % enrofloxacin (2.5 mg/leg, i.m.; Bayer
Table 1 10 Types of miriplatin-lipiodol suspension and emulsions
Healthcare Co. Ltd., Tokyo, Japan) once a day for 3 con-
secutive days and used for our experiments 2 weeks after
implantation wh n the tumors were 15-30 mm in diameter.
Then, we randomly divid d the 50 rabbits with trans-
planted VX2 liver tumors into ten groups. We prepared
fou  types of mixtu es: a suspension of miriplatin (2 mg/
kg) d LPD (0.1 ml/kg) (ML group), an emulsion of
miriplatin dissolved with LPD and contrast medium (MLC
group) or saline (MLS group), and 0.1 ml/kg saline alone
[S (control) group]. In case of the MLC group or MLS
group, the ratio of LPD to the volume of contrast medium
or sal ne was 1:1/4, 1:1/2, 1:1, and 1:2. Consequently, a
otal of 10 solutions were studied (Table 1). The dose of
the dministered agents was based on the maximum dose
used in adult humans with a mean body weight of 60 kg.
Each combination of contrast medium or saline and LPD
was introduced into a disposable syringe, and two syringes
were connected to a three-way stopcock. The syringes were
swung by a pum ing method, which made 20 trips.
Transartenal infusion
Two we ks aft r VX2 implantation we performed transar-
terial infusion under X-ray fluoroscopic guidance. The
r bbits were placed und  general anesthesia with the
above-mentioned method, an incision was made to expose
the right femoral artery, and a 4-Fr sheath (SI sheath; Te-
rumo Clinical Supply, Gifu, Japan) was introduced. Then a
4-Fr cobra-type cathet r (Selecon catheter; Terumo Clinical
Supply) was inserted m the trunk of the cehac artery and
c liac arteriographs were obtained by manually injecting
2 ml of 50 % diluted lopamidol (Bayer Health Care Co.
Ltd., Osaka, Japan.). A 2.トFr microcatheter (Sniper 2
selective type; Terumo Clinical Supply Co. Ltd.) was then
inserted to the left hepatic artery and the suspension and
emulsion which had be n prepared at room temperature
were delivered via a catheter inserted in the left hepatic
a tery, taking care to avoid reflux. Then the catheter and
sheath were removed, and the femoral artery was heated.
Evaluation of antitumor effects
Using 0.3 T MR scans (AIRIS II Comfort, Hitachi Medical
Corp., Tokyo, Japan) we calculated the growth rate of the
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implanted VX2 tumors before and 1 week a鮎r the delivery
of the intra-artenal infusions. The scan parameters were:
field of view 150 mm, Tl-weighted images (TR 300 ms,
TE 14.0 ms, flip angle 90-, slice thickness and interval
3.0 mm, matrix size 256 x 256). The liver tumor volumes
were estimated using Photoshop 7.0.1 (Adobe Systems
Inc., CA, USA). Briefly, two radiologists manually out-
lined the tumors on multiple contiguous MRI slices by
consensus. Then the tumor dimensions on each slice were
added with the assigned values representing the total
number of pixels within the outline. The VX2 tumors easily
created necrosis by themselves, therefore the visible
necrotic lesion observed as an obviously abnormal inten-
sity area was removed in the measurement of tumor vol-
ume. The growth rate (%) was calculated by comparing the
tumor volume recorded before (Vk) and 1 week after (Va)
treatment using the formula: (VJVb) x lOO>
Furthermore, we recorded the sequential changes
observed within the丘rst 24 h in plasma platinum concen-
tration; the platinum concentration surrounding normal
liver tissue and in the tumors were also measured. Plasma
platinum concentrations were assayed immediately after,
and at 10, 30, and 60min, 24h, and 7days after the
inoculations; 1 week after intra-artenal delivery of mi-
riplatin-LPD suspension or emulsion, the rabbits were
sacrificed at the indicated times and the platinum concen-
tration in the tumors and in the normal tissue su汀ounding
the tumors was recorded. The platinum concentrations
were measured at Nac Co., Ltd., Tokyo, Japan. The atomic
absorption spectrometer used was a SIMAA 6000 (Perkin
Elmer, Inc. MA, USA), its detection limit for platinum was
0.05ドg/ml for blood and 0.01トIg/g for tissue.
Statistical analysis
Statistical analysis was performed with Dr. SPSS II for
Windows (SPSS Japan Inc., Tokyo, Japan). To assess
significant differences in the tumor growth rates we used
Tukey's HSD test. Differences in the platinum concentra-
tion in the VX2 tumors and in the normal livers were
determined with a one-tailed Student s Mest. Differences
of p < 0.05 were considered statistically significant.
Results
Transarterial infusion was successful in all rabbits, none
died within 1 week after the procedure.
The tumor growth rate in the VX2-beanng rabbits
inoculated with the ML suspension and saline was
179土32　and　329±71%. It was 126士11, 94士8,
124土13, and 142土44 % in rabbits inoculated with the
」] Springer
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Fig.1Tumorgrowthrate.Thetumorgrowthratetendedtobelower
inMLCandMLSgroups.Therewasasignificantdifferencebetween
theMLgroupandtheMLSl!2group(p-0.02)
MLSemulsionatML:salineratiosof1:1/4,1:1/2,1:1and
2:1respectively,and155土18,107士32,127土12,and
132ア18%inrabbitsinoculatedwiththeMLCemulsion
attheseratios,respectively(Fig.1).Thetumorgrowthrate
wassignificantlylowerinrabbitstreatedwi htheemul-
sionsthaninthesaline-inoculatedcontrols(p<0.05).
AlthoughthetumorgrowthratesmtheMLCandMLS
groupswerelowerthanthatintheMLgroup,mostcom-
parisonsofthegrowthratebetweensuspensionand
emulsiongroupswerenotstatisticallysigni丘cant.How-
ever,thedifferencebetweentumorstreatedwiththeML
suspens onandtheMLSemulsion(ratio1:1/2)wassig-
nificant(p-0.02).
Inalltengroupsthetotalplasmaplatinumconcentration
remainedbelowthelevelofdetectionatallexaminedpost-
inoculationtimepoints.
Theplatinumconcentrationinthetumorandinthe
normallivertissueswas6.09土6.41and5.66土7.56,
respectivelyin血eMLgroup,theco汀espondingvalues
were6.14土6.52and1.88土2.67intheMLS1/4group,
16.43土19.17and1.77土2.64intheMLSl!2group,
8.10士7.98and4.23士5.92intheMLS1group,
8.30士6.91and1.65士1.76intheMLS2group,
4.20士3.95and2.11土2.llintheMLC1/4group,
8.96士8.85and3.34士3.94intheMLC1/2group,
7.25土5.30and3.12土3.98intheMLC1group,and
5.64ア5.77and1.15ア1.47intheMLC2group(Fig.2).
Althoughtherewerenosignificantdifferencesbetweenthe
suspensiongroupandtheemulsiongroups,theplatinum
concentrationinthenormallivertissuewaslowerinMLS
andMLCgroupsthanintheMLgroup,andtheplat num
concentrationinthetumorwashigherintheMLS1/2and
MLC1/2groups.
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Fig. 2 Platinum concentration in tumor and in normal liver tissue.
The platinum concentration in normal liver tissue tended to be lower
in the MLS and MLC groups than in the ML group, and the platinum
concentration in the tumor tended to be higher in the MLS 1/2 group
and MLC 1/2 group
Discussi on
Since 2005, DDPH, a且ne-powder formulation of CDDP,
has been available in Japan for intra-arterial delivery in
HCC patients [21]. Consequently, TACE with a DDPH-
LPD suspension is now widely performed in Japan, and its
efficacy for treating HCC has been reported [11, 21].
However, as DDPH is hydrophilic, its suspension in LPD is
unstable and only a small amount of cisplatin remains m
the tumor over a prolonged period. Most of the agent is
released rapidly from the suspension into systemic circu-
lation, causing systemic side effects.
Miriplatin, a third-generation platinum preparation with
a diaminocyclohexane structure was designed for the
transarterial treatment of HCC. It is a platinum complex
containing myristate, a 14-carbon fatty acid. Due to its
lipophilic properties, it can be suspended easily in LPD by
being shaken gently by hand, and when a suspension of
miriplatin with LPD is administered intra-artenally, LPD
acts as a carrier of miriplatin. ML suspensions selectively
accumulate and persist in the tumor, gradually releasing
active platinum compounds into tumor tissues over a long
time period. Due to this novel attribute, ML suspensions
may exert long-acting antitumor effects, rendering them
superior to other hydrophilic chemotherapeutic agents. In
addition, rapid release into the systemic circulation is
inhibited, resulting in minimal whole-body exposure and a
reduction in adverse systemic side effects such as nausea/
vomiting, renal damage, and other acute toxic events [13,
161. However, the optimal way of suspending miriplatin in
LPD remains still unknown.
Sustained release cannot be expected by merely dis-
solving LPD with anti-cancer drugs, and it has been
reported that sustained release and antitumor effects can be
expected in emulsions of water-in-oil (water droplets dis-
persed in oil) or in suspension form [22】. Moreover, pre-
vious research provided evidence that the ratio of tumor to
nontumorous liver uptake of iodized oil was signi丘cantly
higher with water-in-oil emulsions than with pure iodized
oil or oil-in-water (oil droplets dispersed in water) emuト
sions after intra-arterial hepatic injection in rabbits bearing
VX2 tumors in the liver [23】.
In this study, the tumor growth rate in the minplatin-
LPD emulsion groups was found to be lower than that in
the suspension group, and the platinum concentration in the
normal liver tissue was found to be lower in ML emulsion-
than ML suspension-treated rabbits. This could be because
a droplet of emulsion is larger than a血oplet of suspension
due to t  high visc sity [23], which limits its entrance into
he thin vessels supplying the liver parenchyma, and
increases tumor uptake of minplatin and LPD. Another
reason we considered was that contrast medium or saline
acts as a surfactant for the miriplatin-LPD suspension form
and facilitates the release of platinum丘蝣om it by increasing
its surface area.
In the therapeutic groups, tumors treated with emulsions
in which the LPD: saline and LPDxontrast medium ratios
were 1:1/2 exhibited a lower growth rate and the tumor
platinum concentration in those two emulsion groups was
high r than that in the other groups. This result could be
explained by the difference between water-in-oil emulsion
and oiLin-water emulsion. Among the types of mixtures,
water-in-oil emulsions have been found to exert a stronger
emb lic effect in HCC treatment compared to oil-in-water
mulsions, as well as a greater capacity for sustained
re ease [24]. In our study, the solutions of MLS 1/4, MLS
1/2, MLC 1/4 a d MLC 1/2 were equivalent to water-in-oil
emulsions. However, only 0.075 ml saline or contrast
medium was added in ML suspension in MLS l!4 and
MLC 1/4 solutions, and we assumed that the absolute
volume of saline and contrast medium was too small to
fo m a water-in-oi  emulsion. Another reason was that
adding a greater volume of contrast medium or saline to the
ML suspension caused the concentration of minplatin to
decrease, while the efficacy of ML suspension depended on
the m riplatin concentration. Based on their miriplatm
concentration escalation study, Fujiyama et al. [18] rec-
om end d a dose of 20 me/ml, and the concentration of
miriplatin in the MLS 2 and MLC 2 groups was one-third
of th  recommended dose. Therefore, the adequate dose of
th contrast medium or s hne which was added to LPD was
considered to b  the half volume of LPD.
In our study, the de ect on limit for total plasma plati-
num concentration m blood was 0.05 (xg/ml, and its con-
centration in rabbit blood remained below the detection
level at all t me-points. We attribute this to the highly
・」l Springer
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lipophilic nature of miriplatin; only a limited amount of
platinum is released from ML suspensions as free platinum,
which may account for the undetectable platinum con-
centration in rabbit plasma. Moreover, the small amount of
released miriplatin was present in blood as the active form
of miriplatin hy血ate (DPC) that characteristically binds to
protein in plasma and disappears rapidly [25].
Our study has some limitations. Because of the limited
number of rabbits we could not show significant differ-
ences in the majority of the results, and could show only
the tendency. Another limitation is血at we did not evaluate
liver function in the current experiment, therefore we could
not actually prove the丘nding血at ML emulsion had less
influence on the normal liver tissue than the suspension
form.
Although at present miriplatin is available for clinical
use only in Japan, we expect that its efficacy will be con-
firmed and that it will soon become available elsewhere to
treat the increasing number of patients with liver cancer.
Recently, TACE with drug-eluting beads for HCC treat-
ment has become widely used in western countries 【26,
27], although use of these particles is not permitted m
Japan. Furthermore, the molecular-targeted agent sorafenib
has been found to signi丘cantly prolong survival in patients
with HCC [28] and the guidelines on the use of minplatm
and sorafenib for仙e treatment of HCC have been prepared
[29]. In the near future, a wider choice of treatment for
patients with unresectable HCC would improve their
prognosis.
In this study we did not use embolizing agents such as
gelatin sponge, although Imai et al. [30] reponted that the
addition of embohzing agents to a treatment regimen using
ML suspension could be safely used for HCC. We need to
assess the efficacy and safety of arterial chemoembohza-
tion using ML emulsion and embohzing agents compared
to arterial infusion alone.
In conclusion, this study found that ML emulsions
(water-in-oil) have superior anticancer efficacy compared
to ML suspensions in the treatment of hepatic tumors.
Further clinical trials are necessary to compare the antitu-
mor effects of TACE with ML emulsion to that of TACE
with ML suspension.
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